Natera Corp - NTRA Forward P/S Multiple

Natera Medical (NTRA) - corporate logo

Risks regarding Medicare dependency and development costs are mitigated by the scaling of oncology tests, which expands margins. The expected P/S ratio confirms this trend, where the 15.80 mark records this metric. Consequently, Natera, Inc. (NTRA) maintains a dominant position in genetics, leveraging a massive proprietary dataset and a steady cash flow from non-invasive screening.

NTRA (natera.com) Price to Expected Revenue Ratio history from 07/04/2022 to 11/14/2026

Comprehensive metric breakdowns and analytics for Natera, Inc. (NTRA)

- market price and analyst price targets:
Price Chart Natera, Inc.|NTRA - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Natera|NTRA - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Natera|NTRA - Total Net Assets|Market Capitalization to Book Value Ratio natera.com|NTRA - Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Natera, Inc.|NTRA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital natera.com|NTRA - Company Aggregate Debts|Debt to Book Value Natera Inc|NTRA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Natera|Quick Liquidity natera.com
- net income and valuation multiples indicators:
NTRA - Company Profit|Projected Future Earnings Natera, Inc.|NTRA - Price to Earnings Ratio|Projected Price to Earnings natera.com|NTRA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Natera Corp|NTRA - Operating profit before amortization|Net earnings per share for the last 12 months Natera|NTRA - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months natera.com|NTRA - Earnings per share increase in current year|Earnings growth forecast for next year Natera, Inc.
- issuer revenue and sales details:
NTRA - Revenue and Sales Volume|Company Projected Revenue Natera Corp|NTRA - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Natera Medical
Fundamental company analysis:Natera Corp (NTRA)
Original product of Natera Medical

The efficiency of integrating Natera, Inc. (NTRA) genetic tests into clinical practice directly determines the market value of its future revenue streams. By analyzing the company's forward P/S, an investor assesses the ratio of current market capitalization to expected sales, which allows for the measurement of the premium for technological potential. The dynamics of this metric reflect market confidence in the scaling of partnerships with oncology centers and the resilience of the long-term fundamental valuation.

Key competitors

Forward P/S Multiple HUMA (Humacyte Corp)|Market Cap to Expected Sales Ratio Sera Prognostics, Inc. (SERA)